Pinoxin for the Prevention of Radiation-Induced Skin Injury

ClinicalTrials.gov ID

NCT07545720

Lead Sponsor

Fudan UniversityOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

202Estimated

Last Update Posted

Apr 22, 2026Actual

Start Date

Sep 5, 2024Actual

Primary Completion Date

May 31, 2026Estimated

Completion Date

Dec 31, 2026Estimated

Official Title

A Multicenter, Randomized, Controlled, Double-Blind Clinical Study of Hydrogen-Donor Modified SOD (Pinoxin) for the Prevention of Radiation-Induced Skin Injury

Brief Summary

The incidence of radiation-induced skin injury is high, and effective preventive measures are currently lacking. This study evaluates the role of the skin protective agent Pinoxin in preventing skin injury. Patients are randomly assigned into two prospective groups: treatment group and control group. In treatment group, patients will receive Pinoxin treatment. In control group，patients will receive placebo treatment. The rate of grade 2 or greater skin injury will be analyzed.

Detailed Description

This study is a prospective, randomized controlled, multicenter phase II study, with a design of superior efficacy，to compare the efficacy of Pinoxin and placebo in protecting radiation induced skin injury. We will consecutively enrolled patients who were diagnosed with cancer，and will receive radiotherapy at the dose of 50Gy or higher and radiation field is near skin. A total of 202 patients will be Randomized 1:1 to the treatment group and control group. In treatment group, patients will be sprayed Pinoxin，four times daily (morning, noon, evening, bedtime) from radiotherapy start until 2 weeks post-radiotherapy (continuous, including weekends) .In control group, patiants will received vitamin B12 as placebo. The dosing frequency is the same as that in the treatment group. Unblinding will be triggered if Grade 3 or higher reactions occur. If participants in the placebo control group develop Grade 3 or higher skin injury, they are permitted to use Pinoxin or opt for other appropriate symptomatic treatments.

• Cancer Patients Undergoning Radiotherapy

• pinoxin
• Placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Age ≥ 18 years, regardless of gender.
2. Pathologically diagnosed with a malignant tumor.
3. Scheduled to receive long-course radiotherapy with a total dose of ≥50 Gy, in accordance with standard treatment guidelines.
4. No prior history of radiotherapy.
5. Has provided signed and dated informed consent, indicating that the patient has been informed of all relevant aspects of the study.
6. Patients who are willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion Criteria:

1. History of dermatologic conditions (e.g., vitiligo, psoriasis, etc.) or collagen vascular diseases.
2. Planned hypofractionated radiotherapy regimen.
3. Recent use (e.g., within 3 months) of similar topical protective agents.
4. Known hypersensitivity to any related components or materials.
5. Immunodeficiency disorders.
6. Women who are pregnant or lactating.
7. Any other condition that, in the investigator's judgment, may compromise patient safety or protocol compliance. This includes severe concomitant illnesses (including psychiatric disorders) requiring active treatment, significant laboratory abnormalities, or significant social/familial factors.

Primary Purpose

Prevention

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Single

Lead Sponsor

Fudan UniversityOTHER

zhen_zhang@fudan.edu.cn+86-021-64175590

• A Study for Assessing the Efficacy and Safety of Tetrahydrobiopterin in Radiation-Induced Skin Injury

  NCT05114226

  Unknown statusInterventionalPhase 1Updated Feb 28, 2022
• Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer

  NCT01513278

  CompletedInterventionalPhase 1Phase 2Updated Jul 15, 2013
• Topical Diclofenac for Prevention of Radiation-induced Dermatitis

  NCT06905561

  RecruitingInterventionalNot ApplicableUpdated Apr 3, 2026
• Superoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck Cancer

  NCT07704372

  Not yet recruitingInterventionalPhase 2Updated Jul 15, 2026
• Evaluation of Fenofibrate on Radiation-induced Skin Injury

  NCT03557983

  Unknown statusInterventionalNot ApplicableUpdated Jun 15, 2018
• Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients

  NCT07256119

  RecruitingInterventionalNot ApplicableUpdated Dec 12, 2025